BR112017013956A2 - proteínas de fusão de citocinas - Google Patents

proteínas de fusão de citocinas

Info

Publication number
BR112017013956A2
BR112017013956A2 BR112017013956-1A BR112017013956A BR112017013956A2 BR 112017013956 A2 BR112017013956 A2 BR 112017013956A2 BR 112017013956 A BR112017013956 A BR 112017013956A BR 112017013956 A2 BR112017013956 A2 BR 112017013956A2
Authority
BR
Brazil
Prior art keywords
fusion proteins
cytokine fusion
nucleic acid
acid molecules
present
Prior art date
Application number
BR112017013956-1A
Other languages
English (en)
Other versions
BR112017013956B8 (pt
BR112017013956B1 (pt
BR112017013956A8 (pt
Inventor
Sahin Ugur
GIESEKE Friederike
Backer Ronald
Kreitter Sebastian
Kontermann Roland
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of BR112017013956A2 publication Critical patent/BR112017013956A2/pt
Publication of BR112017013956A8 publication Critical patent/BR112017013956A8/pt
Publication of BR112017013956B1 publication Critical patent/BR112017013956B1/pt
Publication of BR112017013956B8 publication Critical patent/BR112017013956B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção se refere a proteínas de fusão de citocinas e a moléculas de ácido nucleico que codificam essas proteínas de fusão de citoquinas. a presente invenção se refere ainda a células e organismos não humanos. composições farmacêuticas e kits que compreendem as proteínas de fusão de citoquinas ou as moléculas de ácido nucleico que as codificam, bem como a sua utilização como medicamentos.
BR112017013956A 2015-01-15 2016-01-15 Proteínas de fusão de citocinas BR112017013956B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2015/050682 2015-01-15
PCT/EP2015/050682 WO2016112983A1 (en) 2015-01-15 2015-01-15 Cytokine fusion proteins
PCT/EP2016/050773 WO2016113395A1 (en) 2015-01-15 2016-01-15 Cytokine fusion proteins

Publications (4)

Publication Number Publication Date
BR112017013956A2 true BR112017013956A2 (pt) 2018-01-16
BR112017013956A8 BR112017013956A8 (pt) 2019-04-02
BR112017013956B1 BR112017013956B1 (pt) 2024-01-23
BR112017013956B8 BR112017013956B8 (pt) 2024-02-06

Family

ID=52394237

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013956A BR112017013956B8 (pt) 2015-01-15 2016-01-15 Proteínas de fusão de citocinas

Country Status (11)

Country Link
US (2) US10301368B2 (pt)
EP (1) EP3245223B1 (pt)
JP (1) JP6813491B2 (pt)
CN (2) CN113801241A (pt)
AU (1) AU2016207955B2 (pt)
BR (1) BR112017013956B8 (pt)
CA (1) CA2971950A1 (pt)
HK (2) HK1246316A1 (pt)
MX (2) MX2017009153A (pt)
NZ (1) NZ733266A (pt)
WO (2) WO2016112983A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
BR112019017298A2 (pt) * 2017-02-27 2020-04-14 Shattuck Labs Inc proteínas quiméricas à base de tigit e light
CN110337305A (zh) * 2017-02-28 2019-10-15 赛诺菲 治疗性rna
WO2018185247A1 (en) * 2017-04-06 2018-10-11 Universität Stuttgart Tumor necrosis factor receptor (tnfr) binding protein complex with improved binding and bioactivity
US11471490B2 (en) * 2017-07-03 2022-10-18 Torque Therapeutics, Inc. T cells surface-loaded with immunostimulatory fusion molecules and uses thereof
AU2019206573B2 (en) * 2018-01-10 2024-06-06 The General Hospital Corporation Immune cells expressing a chimeric antigen receptor
AU2019276372A1 (en) 2018-06-01 2020-12-24 Evotec International Gmbh Combination therapy for treating hepatitis B virus infection
EP3866846A4 (en) * 2018-10-17 2022-08-31 Albert Einstein College of Medicine METHOD OF INCREASING ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC)
US20230174618A1 (en) * 2019-10-08 2023-06-08 Fred Hutchinson Cancer Center Engineered trimeric cd70 proteins and uses thereof
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
PT2310509E (pt) * 2008-07-21 2015-05-19 Apogenix Gmbh Moléculas de tnfsf em cadeia simples
AU2010224094A1 (en) * 2009-03-13 2011-09-22 The Trustees Of The University Of Pennsylvania OX40/TRAIL fusion proteins
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
US20150114305A1 (en) * 2012-04-24 2015-04-30 Nordischer Maschinenbau Rud. Baader Gmbh + Co. Kg Fish corral and fish accumulator
EP2970427B1 (en) * 2013-03-15 2019-12-25 Stone, Geoffrey W. Composition comprised of antigen linked to a tnf superfamily ligand

Also Published As

Publication number Publication date
US10808019B2 (en) 2020-10-20
CN107428842B (zh) 2021-10-01
US20180002392A1 (en) 2018-01-04
CN107428842A (zh) 2017-12-01
JP6813491B2 (ja) 2021-01-13
MX2017009153A (es) 2018-02-01
JP2018503379A (ja) 2018-02-08
BR112017013956B8 (pt) 2024-02-06
AU2016207955A1 (en) 2017-07-20
BR112017013956B1 (pt) 2024-01-23
US20190276511A1 (en) 2019-09-12
AU2016207955B2 (en) 2020-05-28
NZ733266A (en) 2022-04-29
HK1246315A1 (zh) 2018-09-07
EP3245223A1 (en) 2017-11-22
CA2971950A1 (en) 2016-07-21
US10301368B2 (en) 2019-05-28
WO2016112983A1 (en) 2016-07-21
CN113801241A (zh) 2021-12-17
BR112017013956A8 (pt) 2019-04-02
HK1246316A1 (zh) 2018-09-07
MX2021010668A (es) 2021-09-28
EP3245223B1 (en) 2020-03-04
WO2016113395A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
BR112017013956A2 (pt) proteínas de fusão de citocinas
CY1124740T1 (el) Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης
CY1123642T1 (el) Αντισωματα enanti-pd-1
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
CO2018002703A2 (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
CY1118168T1 (el) Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma
BR112016015105A2 (pt) Conjugados var2csa-droga
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201492221A1 (ru) Полипептиды, имеющие активность трансгалактозилирования
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
BR112017013576A2 (pt) produção melhorada de lipídios de núcleo em leveduras oleaginosas
AR092879A1 (es) Proteinas de fusion de g3p como agentes de union a amiloide
UY34373A (es) Moléculas de ácido nucleico que se dirigen a pp1-87b y confieren resistencia a plagas de coleópteros.
WO2014145870A3 (en) Novel compositions, methods and kits for blood typing

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: BIONTECH RNA PHARMACEUTICALS GMBH (DE) , UNIVERSIT

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: UNIVERSITAET STUTTGART (DE) ; TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GGMBH (DE) ; BIONTECH SE (DE)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2016, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2768 DE 23/01/2024, QUANTO AO ITEM (73) ENDERECO DO TITULAR.